The cycloxygenase 2 (COX-2) story: It's time to explain, not inflame

Guillermo Salinas, Umamahesh Rangasetty, Barry F. Uretsky, Yochai Birnbaum

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Despite initial promising reports that anti-inflammatory properties of cycloxygenase-2 (COX-2) inhibitors may confer anti-atherosclerosis effects and stabilize the atherosclerotic plaque, subsequent data from long-term clinical trials have shown that selective COX-2 inhibitors are associated with increased risk of cardiovascular events. The commonly cited explanation is that selective inhibition of COX-2 leads to depletion of prostacyclin, whereas the production of pro-thrombotic thromboxane by means of cycloxygenase-1 (COX-1) is unopposed. This hypothesis seems unlikely as the overall explanation, because low-dose aspirin does not decrease the increased risk associated with COX-2 inhibitors. Moreover, the risk associated with nonselective COX inhibitors may be similar to selective COX-2 inhibitors. Alternative hypotheses include (1) elevated blood pressure, (2) abnormal vascular remodeling, (3) inhibition of protective mechanisms against ischemia-reperfusion injury, and (4) inhibition of 15-epi-lipoxin production. Varying results in different experimental models may be related to the fact that COX-2 is involved in numerous cellular functions. Inhibiting COX-2 in inflammatory cells may have favorable effects, whereas in organs such as the heart and brain and/or blood vessels may have deleterious effects. Currently, the "selective COX-2 inhibitors" are not selective in the sense that they inhibit COX-2 in all tissues without predilection to inflammatory cells and, as a result, may summate to increase the risk of cardiovascular events.

Original languageEnglish (US)
Pages (from-to)98-111
Number of pages14
JournalJournal of Cardiovascular Pharmacology and Therapeutics
Volume12
Issue number2
DOIs
StatePublished - Jun 2007

Fingerprint

Lipoxins
Thromboxanes
Epoprostenol
Atherosclerotic Plaques
Reperfusion Injury
Aspirin
Blood Vessels
Atherosclerosis
Anti-Inflammatory Agents
Theoretical Models
Clinical Trials
Blood Pressure
Brain
Vascular Remodeling

Keywords

  • Cardiovascular disease
  • Cycloxygenase-2 (COX-2)
  • Inflammation
  • Nonsteroidal antiinflammatory drugs

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

The cycloxygenase 2 (COX-2) story : It's time to explain, not inflame. / Salinas, Guillermo; Rangasetty, Umamahesh; Uretsky, Barry F.; Birnbaum, Yochai.

In: Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 12, No. 2, 06.2007, p. 98-111.

Research output: Contribution to journalArticle

Salinas, Guillermo ; Rangasetty, Umamahesh ; Uretsky, Barry F. ; Birnbaum, Yochai. / The cycloxygenase 2 (COX-2) story : It's time to explain, not inflame. In: Journal of Cardiovascular Pharmacology and Therapeutics. 2007 ; Vol. 12, No. 2. pp. 98-111.
@article{cbd1e649fd334bbb867a8b9ad658069a,
title = "The cycloxygenase 2 (COX-2) story: It's time to explain, not inflame",
abstract = "Despite initial promising reports that anti-inflammatory properties of cycloxygenase-2 (COX-2) inhibitors may confer anti-atherosclerosis effects and stabilize the atherosclerotic plaque, subsequent data from long-term clinical trials have shown that selective COX-2 inhibitors are associated with increased risk of cardiovascular events. The commonly cited explanation is that selective inhibition of COX-2 leads to depletion of prostacyclin, whereas the production of pro-thrombotic thromboxane by means of cycloxygenase-1 (COX-1) is unopposed. This hypothesis seems unlikely as the overall explanation, because low-dose aspirin does not decrease the increased risk associated with COX-2 inhibitors. Moreover, the risk associated with nonselective COX inhibitors may be similar to selective COX-2 inhibitors. Alternative hypotheses include (1) elevated blood pressure, (2) abnormal vascular remodeling, (3) inhibition of protective mechanisms against ischemia-reperfusion injury, and (4) inhibition of 15-epi-lipoxin production. Varying results in different experimental models may be related to the fact that COX-2 is involved in numerous cellular functions. Inhibiting COX-2 in inflammatory cells may have favorable effects, whereas in organs such as the heart and brain and/or blood vessels may have deleterious effects. Currently, the {"}selective COX-2 inhibitors{"} are not selective in the sense that they inhibit COX-2 in all tissues without predilection to inflammatory cells and, as a result, may summate to increase the risk of cardiovascular events.",
keywords = "Cardiovascular disease, Cycloxygenase-2 (COX-2), Inflammation, Nonsteroidal antiinflammatory drugs",
author = "Guillermo Salinas and Umamahesh Rangasetty and Uretsky, {Barry F.} and Yochai Birnbaum",
year = "2007",
month = "6",
doi = "10.1177/1074248407301172",
language = "English (US)",
volume = "12",
pages = "98--111",
journal = "Journal of Cardiovascular Pharmacology and Therapeutics",
issn = "1074-2484",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - The cycloxygenase 2 (COX-2) story

T2 - It's time to explain, not inflame

AU - Salinas, Guillermo

AU - Rangasetty, Umamahesh

AU - Uretsky, Barry F.

AU - Birnbaum, Yochai

PY - 2007/6

Y1 - 2007/6

N2 - Despite initial promising reports that anti-inflammatory properties of cycloxygenase-2 (COX-2) inhibitors may confer anti-atherosclerosis effects and stabilize the atherosclerotic plaque, subsequent data from long-term clinical trials have shown that selective COX-2 inhibitors are associated with increased risk of cardiovascular events. The commonly cited explanation is that selective inhibition of COX-2 leads to depletion of prostacyclin, whereas the production of pro-thrombotic thromboxane by means of cycloxygenase-1 (COX-1) is unopposed. This hypothesis seems unlikely as the overall explanation, because low-dose aspirin does not decrease the increased risk associated with COX-2 inhibitors. Moreover, the risk associated with nonselective COX inhibitors may be similar to selective COX-2 inhibitors. Alternative hypotheses include (1) elevated blood pressure, (2) abnormal vascular remodeling, (3) inhibition of protective mechanisms against ischemia-reperfusion injury, and (4) inhibition of 15-epi-lipoxin production. Varying results in different experimental models may be related to the fact that COX-2 is involved in numerous cellular functions. Inhibiting COX-2 in inflammatory cells may have favorable effects, whereas in organs such as the heart and brain and/or blood vessels may have deleterious effects. Currently, the "selective COX-2 inhibitors" are not selective in the sense that they inhibit COX-2 in all tissues without predilection to inflammatory cells and, as a result, may summate to increase the risk of cardiovascular events.

AB - Despite initial promising reports that anti-inflammatory properties of cycloxygenase-2 (COX-2) inhibitors may confer anti-atherosclerosis effects and stabilize the atherosclerotic plaque, subsequent data from long-term clinical trials have shown that selective COX-2 inhibitors are associated with increased risk of cardiovascular events. The commonly cited explanation is that selective inhibition of COX-2 leads to depletion of prostacyclin, whereas the production of pro-thrombotic thromboxane by means of cycloxygenase-1 (COX-1) is unopposed. This hypothesis seems unlikely as the overall explanation, because low-dose aspirin does not decrease the increased risk associated with COX-2 inhibitors. Moreover, the risk associated with nonselective COX inhibitors may be similar to selective COX-2 inhibitors. Alternative hypotheses include (1) elevated blood pressure, (2) abnormal vascular remodeling, (3) inhibition of protective mechanisms against ischemia-reperfusion injury, and (4) inhibition of 15-epi-lipoxin production. Varying results in different experimental models may be related to the fact that COX-2 is involved in numerous cellular functions. Inhibiting COX-2 in inflammatory cells may have favorable effects, whereas in organs such as the heart and brain and/or blood vessels may have deleterious effects. Currently, the "selective COX-2 inhibitors" are not selective in the sense that they inhibit COX-2 in all tissues without predilection to inflammatory cells and, as a result, may summate to increase the risk of cardiovascular events.

KW - Cardiovascular disease

KW - Cycloxygenase-2 (COX-2)

KW - Inflammation

KW - Nonsteroidal antiinflammatory drugs

UR - http://www.scopus.com/inward/record.url?scp=34249660140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249660140&partnerID=8YFLogxK

U2 - 10.1177/1074248407301172

DO - 10.1177/1074248407301172

M3 - Article

C2 - 17562780

AN - SCOPUS:34249660140

VL - 12

SP - 98

EP - 111

JO - Journal of Cardiovascular Pharmacology and Therapeutics

JF - Journal of Cardiovascular Pharmacology and Therapeutics

SN - 1074-2484

IS - 2

ER -